PRIFYSGOL BANGOR / BANGOR UNIVERSITY

PRIFYSGOL
BANGOR
UNIVERSITY

CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer

Smith, Danielle; Lunj, Sapna; Adamson, Anthony; Nagarajan, Sankari; Smith, Tim; Reeves, Kim; Hoskin, Peter; Choudhury, Ananya

Nature Reviews Urology

DOI:
10.1038/s41585-024-00901-y

E-pub ahead of print: 01/07/2024

Peer reviewed version

Cyswllt i'r cyhoeddiad / Link to publication

Dyfyniad o'r fersiwn a gyhoeddwyd / Citation for published version (APA):
Smith, D., Lunj, S., Adamson, A., Nagarajan, S., Smith, T., Reeves, K., Hoskin, P., & Choudhury, A. (2024). CRISPR–Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder cancer. *Nature Reviews Urology*, *21*. Advance online publication. https://doi.org/10.1038/s41585-024-00901-y

Hawliau Cyffredinol / General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?

Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

10. Jan. 2025

CRISPR-Cas9 potential for identifying novel therapeutic targets in muscle-invasive bladder

Danielle J Smith[1], Sapna Lunj[1], Antony D Adamson[3], Sankari Nagarajan[2], Tim AD Smith[1,5], Kimberley J Reeves[1], Peter J Hoskin[1,4], Ananya Choudhury[1,4]*

[1]Division of Cancer Sciences, University of Manchester, UK.

[2]Division of Molecular and Cellular Function, University of Manchester, UK.

[3]Faculty of Biology, Medicine and Health Research and innovation, University of Manchester, UK.

[4]The Christie NHS Foundation Trust, Manchester, UK.

[5] Nuclear Futures Institute, Bangor University, UK

*Email:danielle.smith-2@manchester.ac.uk

Abstract

Gene editing technologies help identifying the genetic perturbations driving tumour initiation, growth, metastasis, and resistance to therapeutics. This wealth of information highlights tumour complexity and is driving cancer research towards precision medicine approaches based on an individual's tumour genetics. Bladder cancer is the 10th most common cancer in the UK, with high rates of relapse and low survival rates for patients with muscle-invasive disease. Muscle-invasive bladder cancer (MIBC) is highly heterogenous and encompasses multiple molecular subtypes, each with different responses to therapeutics. This evidence highlights the need to identify innovative therapeutic targets to address the challenges posed by this heterogeneity. CRISPR-Cas9 technologies have been used to advance our understanding of MIBC and determining novel drug targets through the identification of drug resistance mechanisms, targetable cell-cycle regulators as well as novel tumour suppressor and oncogenes. However, the use of these technologies into the clinic remains a substantial challenge and will require careful consideration of dosage, safety, and ethics. clustered regularly interspaced short palindromic repeats-CRISPR-associated protein (CRISPR-Cas9) offers considerable potential for revolutionizing bladder cancer therapies, but substantial validation research is required before these technologies can be used in the clinical setting.

[H1] Introduction

Advances in gene editing technologies provided vast information about the genetic perturbations driving tumour initiation, growth, metastasis, and resistance to therapeutics, highlighting the need for precision medicine approaches based on an individual's tumour genetics. Gene editing technologies enable to study the phenotypic effects of genes at an individual level, up to genome-wide scale. Traditional nuclease-based gene targeting methods, such as zinc finger nucleases (ZFNs) and transcription activator-like effector nucleases (TALENs), were the main used for carrying out genetic modifications [1]. However, these methods have been replaced by the development of the clustered regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated protein (Cas) technologies, which have increased efficiency, reduced costs, and are easier to design[2] . These

39 CRISPR-Cas technologies are a highly valuable research tool for studying many aspects of cancer
40 research, including genetic drivers of tumorigenesis, invasion, and drug resistance, which can lead to
41 the detection of novel therapeutic targets[3–5].

42 Bladder cancer is the 11th most common cancer in the UK across males and females but the 8th most
43 common cancer in males in the UK, with over 10,000 diagnoses in the UK every year [6]. In general,
44 non-muscle invasive bladder cancer (NMIBC) is highly treatable with good survival statistics [7].
45 However, relapse is common, and ~20% of NMIBC instances progress to muscle-invasive disease,
46 which is associated with a 5-year survival rate of only 45% [8], with nodal and metastatic disease
47 considered to be incurable. The current standard of care for MIBC includes chemotherapy, radical
48 cystectomy, or radiotherapy with a radiosensitiser, and in metastatic disease, immunomodulation [9–
49 11]. Targeted therapies currently available for the treatment of bladder cancer are limited. However,
50 some therapies such as PDL1 and FGFR3 inhibitors have been approved as second-line therapies to
51 be provided following failure of first-line treatments [12]. However these second-line therapies have
52 limited therapeutic benefit, as resistance remains a substantial problem [13–15].

53 Muscle-invasive bladder cancer (MIBC) can be categorised into six molecular subtypes: luminal
54 papillary; luminal non-specified; luminal unstable; stroma-rich; basal/squamous; and
55 neuroendocrine-like [16–18]. These subtypes differ in treatment response and intrinsic therapy
56 resistance, which leads to substantial negative impact in patients. Hence, further advances are
57 needed to identify innovative therapeutic strategies to address the challenges posed by both the
58 intra-tumour and inter-tumour heterogeneity of bladder cancer. CRISPR technologies could give
59 valuable insight in this field.

60 In this Perspective, we aim to summarise how CRISPR-Cas9 gene editing technologies have been
61 used to advance our understanding of MIBC for novel target discovery, and how these technologies
62 could be further used to improve patient outcomes.

63 **[H1] CRISPR Cas mechanisms and methodologies**

64 **Within genetic engineering, CRISPR Cas has become the key technology utilised for the**
65 **specific and precise targeting of DNA sequences. Among the CRISPR Cas systems, the most**
66 **commonly used is CRISPR Cas9 due to its simplicity and versatility.**

67 **[H2] CRISPR-Cas9**

68 Advances in gene editing technologies enabled researchers to study phenotypes and functional
69 effects of mutations or knock-out of specific genes. One of the main technologies currently used to
70 this aim is CRISPR-Cas9, which enables us to target any gene of interest with high specificity for a
71 variety of purposes. CRISPR-Cas9 is the CRISPR system based on the Cas9 endonuclease from *S.*
72 *pyogenes* 'SpyCas9', and is the most widely used gene editing system[19]. CRISPR-Cas9 has been
73 adapted from a naturally occurring gene disabling system in bacteria, in which CRISPR-associated
74 protein (Cas) nuclease activity is guided to specifically degrade phages' DNA as a defence mechanism
75 against invading viruses[20]. In mammalian cells, CRISPR-Cas9 has been re-purposed to knock-out or
76 modify target genes [20,21], supporting the identification of genetic drivers of disease progression and
77 therapeutic resistance. This discovery by Emmanuelle Charpentier and Jennifer Doudna was so
78 instrumental in genetics research that it was awarded the Nobel prize in chemistry in 2020.

79 The CRISPR-Cas9 system induces double-strand breaks (DSBs) in DNA using the Cas9 endonuclease
80 bound to a single-guide RNA molecule (sgRNA), which guides the Cas9 to the DNA target site (Box1).
81 Cas9 is the most commonly used CRISPR system, but other CRISPR methodologies are available
82 involving alternative forms of Cas9, such as SauCas9, as well as other Cas proteins including Cas12,

Cas13 and Cas3 [22,23].DSBs are subsequently repaired through non-homologous end joining (NHEJ), which, however, is highly error prone[24], or homology-directed repair (HDR), which is highly precise and can be used to induce mutations of choice within the DNA [25].Other repair pathways exist, such as microhomology-mediated end joining, but in this Perspective, we will focus on the most used NHEJ and HDR [26].

[H2] CRISPR-Cas methodologies

Since the development of CRISPR Cas gene editing, there have been extensive advancements in these technologies. This has meant there is now a wide breadth of options available for studying the genetic landscape of cancer.

[H3] CRISPRa and CRISPRi libraries

CRISPR-Cas9 technology is most commonly used to achieve gene knock-out by inducing a DSB in DNA target genes (Figure 1A). However, in the past 10 years this technology has been further adapted to alter target gene expression using a catalytically inactive form of the Cas9 endonuclease (dCas9), which lacks the ability to cut DNA, but can still bind target DNA sequences guided by a sgRNA. CRISPR-activating (CRISPRa) and CRISPR-inteference (CRISPRi) are two systems in which dCas9 is bound to a transcriptional effector (Fig. 2B) or to a transcriptional repressor, (Fig. 2C), respectively, to alter signalling downstream from a target gene of interest without causing permanent genetic changes [27]. In CRISPRa, dCas9 binding to the promoter region of the gene of interest induces recruitment of transcription activators, such as VP64 and the synergistic activation mediator (SAM), leading to increased gene expression [28,29]. Conversely, in CRISPRi, sgRNA binding to the promoter region prevents transcription-factor binding, leading to reduced mRNA transcription [30]. Using these inducible systems enables to study essential genes, which is not possible during knock-out screening. Furthermore, these systems induce transient changes in gene expression, which can be used, for example, to simulatethe responses of cancer cells to selection pressures such as that induced by drugs, thereby increasing our understanding of these processes [31]

[H3] Base editing and prime editing

Further derivatives of CRISPR-Cas9 techniques include base editing (Fig. 2D) and prime editing (Fig. 2E), which enable to induce point mutations and small changes in the genome without inducing a DSB. These strategies reduce the chance of unwanted addition of indels whilst maintaining high efficiency. Base editing is carried out using CRISPR-Cas9 base editors, which consist of a catalytically inactive form of Cas9 (dCas9) or, more commonly, Cas9 D10A nickase, which only nicks the DNA[32,33]. Deaminases cytidine or adenine deaminase are tethered to this complex, and can direct DNA base substitutions without the need for DSB [34,35]. This technology offers the potential to correct cancer-causing genetic mutations or create desired genetic variations to observe the phenotypic outcome of individual base changes [36]. Similarly, prime editing is a modification of the CRISPR-Cas9 system that also leverages the RNA-guided binding of a Cas9 form that is unable to generate DSBs. In this system, a H820 nickase Cas9 is fused to an engineered reverse transcriptase, which is directed to genomic targets by a prime editing guide RNA (pegRNA). The pegRNA contains an RNA template that can be copied into the nicked genome by the reverse transcriptase [37,38]. This approach enables to achieve precise DNA edits without the need for a DSB or a supply of exogenous DNA.

[H2] Whole-genome knockout CRISPR screening

Whole genome CRISPR-Cas9 knockout screens (WGCS) consists in ablating gene expression on a genome-wide scale and studying the resulting phenotypic alterations to elucidate the relationship between genotype and phenotype In this approach, an sgRNA library (consisting of sgRNA against every gene in the genome, or a subset of genes) is transduced into Cas9-expressing target cells at a moiety of infection low enough to result in each cell receiving one single sgRNA, leading to a

129 population of cells each with a different gene knock-out [39]. This population of genetically altered cells
130 can then be exposed to different conditions of interest or challenges. The DNA from cells surviving
131 the selective pressure can be extracted and sequenced to determine which guides (genes) are
132 enriched or depleted using the integrated sgRNA as a barcode [40,41]. This approach provides
133 information about the roles of specific genes and how these genes are affected in different
134 conditions. Following the discovery of new technologies such as CRISPRa and CRISPRi, CRISPR
135 screens are also carried out using different Cas9 variants such as dCas9, Cas12 and Cas13, which
136 induce altered gene expression instead of gene knockout [42–44].

137 **[H1] CRISPR-Cas9 gene editing in MIBC research for target discovery**

138 Before the widespread use of CRISPR, siRNA gene knockdown was a popular method for
139 manipulating gene expression. Silencing of the receptor-interacting protein kinase 4 (RIPK4)
140 through siRNA in multiple bladder cancer mouse models including an in-situ bladder tumour mouse
141 model showed reduction in tumour stage[45]. However, this methodology has not successfully moved
142 to use into the clinic[46,47] owing to issues including the lack of longevity of response to siRNA, due
143 to siRNA modifications being transient as well as safety considerations. CRISPR-based technologies
144 have overcome these issues, as gene knock-out or knock-in achieved through CRISPR-Cas are
145 permanent genetic alterations. Furthermore, CRISPR screens using CRISPRa, CRISPRi, prime and
146 base editing enable us to introduce a broader range of alterations and to test a wider range of
147 effects than previously used techniques.

148 CRISPR gene editing techniques have widespread utility in cancer research, facilitating the
149 identification of genetic drivers involved in tumour progression and drug resistance. The ultimate
150 goal of these approaches is to uncover novel drug targets to improve the efficacy of cancer
151 treatments. The heterogeneity and wide range of molecular subtypes in bladder cancer makes
152 CRISPR-based screening approaches particularly relevant and led to rapid advances in understanding
153 how to improve patient outcomes (Fig.2).

154 **[H2] CRISPR-Cas to identify mechanisms of chemotherapy resistance**

155 Chemotherapy resistance is prevalent in individuals with MIBC, and is mainly attributed to acquired
156 resistance mechanisms within the tumour, including overexpression of drug efflux pumps, activation
157 of anti-apoptotic signalling pathways and increased DNA repair[48–51]. However, the exact
158 understanding of these mechanisms remains limited, leading to treatment failure and disease
159 progression. CRISPR screening methods have been used to help identify the genetic factors
160 contributing to these acquired resistance mechanisms.

161 In MIBC, WGCSs have been used to identify multiple genes controlling chemotherapy sensitivity and
162 resistance. Cisplatin stands as a primary option among chemotherapeutic agents for the treatment of
163 MIBC[9], underscoring the importance of comprehending both resistance mechanisms and the genetic
164 factors influencing chemotherapy sensitivity in tumours. Results from a WGCS in MIBC cells showed
165 that Schlafen 11 (*SLFN11*) knockout caused chemotherapy resistance[52]. This result was validated both
166 in vivo in animal models and in patient tumour samples[52]. Following cisplatin-induced DNA damage,
167 SLFN11 acts as a regulator of cell-cycle progression by interacting with the Mediator of DNA damage
168 checkpoint 1 protein (MDC1) [52]. Results from this WCGS suggest that high SLFN11 expression in
169 patients could be an indicator that neoadjuvant chemotherapy (NAC) would have high efficacy [53].
170 Considering this chemo-sensitizing effect of SLFN11 overexpression across multiple cancer types [54],
171 epigenetic modification of *SLFN11* to increase expression has been hypothesized to be an effective
172 novel therapeutic strategy for re-sensitisation of tumours to cisplatin-based chemotherapy [55].
173 Multiple inhibitors of epigenetic modulators targeting DNA methyl transferases, histone lysine
174 methyltransferases, or histone lysine acetyltransferases have been explored in clinical trials and

175 showed promise in combination with current standard of care treatments including chemotherapy
176 and immunotherapy in a range of tumour types, indicating future potential for [56]novel therapeutics.

177 In another WGCS study in MIBC, *MSH2* knockout was shown to confer resistance to cisplatin-based
178 chemotherapy through downregulation of DNA-damage response mechanisms [57]. This reduced DNA-
179 damage response is probably mediated by MSH2-mediated recruitment of ERCC1, a known marker of
180 cisplatin resistance, during DNA mismatch repair [58]. Moreover, low MSH2 expression in tumour
181 samples from patient with MIBC positively correlated with reduced overall survival and poor
182 prognosis[59], indicating that MSH2 could act as a predictive biomarker for cisplatin sensitivity. Other
183 mechanisms of cisplatin resistance include onset of apoptosis orchestrated by the circular RNA
184 circLIFR which interacts with MSH2 [60].

185 In another study, the heterogenous nuclear ribonucleoprotein U (*HNRNPU*) gene has been identified
186 by WGCS as an important gene for cisplatin resistance in T24 MIBC cells, as *HNRNPU* knockout
187 inhibited cell proliferation and migration and increased apoptosis in response to cisplatin. This effect
188 was shown to be mediated by the modulation of the HNRNPU downstream target neurofibromin 1
189 gene (*NF1*), a tumour suppressor gene with a role in chemosensitivity . HNRNPU CRISPR Cas9
190 knockout induced upregulation of NF1 in T24 cells, inducing chemosensitivity to cisplatin[61]. The
191 increased chemosensitivity observed in HNRNPU knockout cells was reversed by the knockout of
192 *NF1*, highlighting that the effect of HNRNPU knockout was mediated by NF1 upregulation [61].
193 Furthermore, analysis of samples in The Cancer Genome Atlas (TCGA) showed that high HNRNPU
194 expression is positively correlated with low survival rates in patients with MIBC [61]. Thus, inhibition of
195 HNRNPU has been identified as a potential target for re-sensitisation of tumours to cisplatin-based
196 therapy [62].

197 Multiple drivers of chemotherapy resistance have been identified using CRISPR technologies, but
198 further studies are needed to validate these targets in vivo in order to move towards a clinical trial
199 setting. Additionally, to date, only cisplatin resistance and sensitivity have been studied, although
200 multiple other chemotherapies are used in bladder cancer treatment. Thus, further CRISPR screening
201 approaches could be used to identify genetic drivers of response to different chemotherapy agents..

202 **[H2] CRISPR-Cas to identify mechanisms of radiotherapy resistance**

203 Radiotherapy has a widespread use in the treatment of bladder cancer, but very few studies have
204 been carried out using CRISPR to determine the genetic drivers of radioresistance mechanisms.
205 Hypoxia is a crucial driver of therapeutic resistance in bladder cancer to radiotherapy, as well as to
206 other therapeutics, but the mechanisms underlying this resistance are poorly understood.
207 Radiotherapy is given in combination with the radiosensitiser carbogen and nicotinamide (CON) as a
208 standard of care recommended by the National Institute for Health and Care Excellence (NICE) in the
209 UK. CON is used to alleviate tumour hypoxia to re-sensitise the tumour to the radiotherapy [63] and has
210 been shown to increase overall survival by 14 months [64], highlighting the therapeutic benefit of
211 targeting hypoxia. However, CON only alleviates the low oxygen tension but does not eradicate the
212 hypoxic radiotherapy-resistant phenotype that has evolved. Thus, further research using CRISPR-Cas9
213 screens to identify novel drivers of hypoxia-induced treatment resistance is of paramount
214 importance in bladder cancer research. This approach could also be used to identify drivers of
215 pseudohypoxia or any oxygen-independent HIF activation.

216 **[H2] Immunotherapy**

217 **Bladder cancer therapy has been enhanced throught the development of immunotherapy aiding in**
218 **tumour treatment in both the first line and second line treatment settings. These therapies have**

been found to be effective in the treatment of MIBC, however there is large scope for more use of these therapies [65]. CRISPR Cas based research is an essential tool in understanding and uncovering novel immunotherapy targets.

[H3] CRISPR screening to uncover gene targets for immunotherapy

A number of immunotherapies are being investigated for clinical use to treat MIBC. Inhibitors of programmed cell death protein-1 (PD1), programmed death ligand 1 (PDL1), and cytotoxic T-lymphocyte antigen 4 (CTLA4) have been particularly studied. Specifically, in a trial including patients with MIBC, combination therapy with the PD1 inhibitor nivolumab plus gemcitabine and cisplatin chemotherapies increased clinical complete response reducing the need for radical cystectomy [66]. Inhibition of these proteins prevents the suppression of T cell-driven tumour killing. CRISPR gene editing could help understand the mechanisms underlying this phenomenon. However, this approach has not yet been well-exploited in bladder cancer research.

Understanding the role of peripheral circulating blood lymphocytes and immune checkpoint-related protein expression on tumours is of high interest. A study was carried out on peripheral blood mononuclear cells from patients with bladder cancer and healthy donors to determine the differences in the expression levels of the immune checkpoint molecules PD1 and CTLA4. Expression levels of both PD1 and CTLA4 were shown to be elevated in patients with MIBC compared with healthy donors[67] . Additionally, CTLA4 was silenced on CTLs using CRISPR-Cas9 in MIBC cells co-cultured with control cytotoxic T lymphocytes (CTL). *CTLA4* KO was shown to enhance anti-tumour activity of CTL through increasing apoptosis in co-cultured MIBC cells, highlighting the role of CTLA4 in bladder cancer immune system evasion [67] . *CTLA4* KO-mediated increased cytotoxicity was also confirmed in in vivo mouse models of bladder cancer [67]. These results indicate that high CTLA4 expression is a marker of CTL exhaustion, and *CTLA4* KO counteracts this phenotype. Thus, immune checkpoint modification of CTLA could be an effective combination treatment with first-line therapies, chemotherapy and radiotherapy, to reduce T cell exhaustion and cancer immune evasion [67].

[H3] CRISPR as a tool to uncover mechanisms of response to immunotherapies

Tumours might become resistant to checkpoint inhibitors. Thus, CRISPR is being used to identify mechanisms of resistance associated with immune checkpoint inhibitors, specifically PD1. In a study in bladder cancer cells, dual CRISPR-Cas9 knockout of the checkpoint blockade *PD1* and the long non-coding RNA urothelial carcinoma associated 1 (UCA1) enhanced PD1-induced anti-tumour activity both in vitro and in vivo mouse model, reducing tumour growth and increasing survival [68]. In humanized SCID mice xenografted with a human bladder cancer cell line (5637) knockout for PD1 and UCA1, a shift in the tumour microenvironment— from immunosuppressive to stimulatory —was observed, and occurred through enhanced expression of Th1-associated immune-stimulating genes [69]. These results highlight how the efficacy of PD1 immunotherapies could be increased using a combination approach. However, this dual targeting of PD1 and UCA1 has yet to be tested in a clinical setting. Furthermore, lncRNAs based therapies are still within early stages due to issues such as the variability of lncRNA expression patterns between different patients[70]

[H2] Synthetic lethality studies using CRISPR-Cas9

When looking for novel cancer therapies, targeting only one gene might be insufficient, as, often, more than one gene mutation can be responsible for a phenotypic change. Thus, high interest has been growing around identifying synthetic lethal partners driving tumour progression. The gene pair of the CREB binding protein (*CBP*) and *p300* — which are histone acetyltransferases acting as

transcriptional coactivators— have been identified as potential therapeutic targets in other cancer types(such as breast and prostate cancer) [71]. The potential of these gene as therapeutic targets in bladder cancer has not been studied. However, CRISPR interference technology using the dCas9 system was used to achieve dual inhibition of these genes in bladder cancer cells. Fusion of the Kruppel-associated box1 (KRAB) is commonly known to increase effectiveness of gene silencing of dCas9 [31]. To make this inhibition bladder cancer cell-specific, the dCas9-KRAB system was combined with the hUPII and hTERT promoters, which are cancer- and bladder-specific promoters, respectively [72]. This strategy successfully prevented dual gene silencing in normal bladder urothelial cells. Dual suppression of *CBP* and *p300* in MIBC cells inhibited cell growth and increased apoptosis through a reduction of c-MYC expression [73]. This bladder cancer cell-specific approach enables to selective killing bladder cancer cells without causing damage to normal urothelial cells which, if successfully transferred into the in vivo setting, could provide a novel therapeutic approach in the treatment of bladder cancer. To date, this work has not been validated in in vivo models. Thus, translation of this targeting strategy in the clinic remains highly speculative.

[74]**[H2] Using CRISPR-Cas to achieve cell-cycle regulation**

Cyclin dependent kinases (CDKs) have a central role in cell-cycle regulation and, therefore, have become attractive targets for cancer therapy. CDK inhibitors have been developed to specifically block the abnormal activation of CDK-cyclin complexes in cancer cells, causing cell-cycle arrest and inducing apoptosis. Some CDK inhibitors have been approved for the treatment of certain types of cancer, such as breast cancer [75]. However, none of these inhibitors have yet been approved for use in bladder cancer owing to lack of response in clinical trials [76]. A whole-genome CRISPR-dCas9 activation screen was carried out in MIBC cells to identify resistance mechanisms of bladder cancer to CDK4 and CDK6 inhibitors [77]. Enrichment of sgRNAs indicated genes that mediated CDK4 and CDK6 inhibitor resistance. Nearly 1000 targets were identified in this screen, which were then analysed to determine signalling pathways commonly associated with CDK4 and CDK6 resistance[77]. The vast number of enriched guides highlights the complexity of CDK4 and CDK6 inhibitor resistance. Multiple signalling pathways were identified as contributors to this resistance mechanism, such as receptor tyrosine kinase and PI3K—AKT signalling pathways[77]. These findings suggest that a panel of predictive resistance markers could be created to stratify patients, and combination therapy involving CDK4 and CDK6 inhibitors along with inhibitors of the identified resistance markers could be used, potentially improving treatment outcomes [78].

[H2] CRISPR-Cas to study tumour suppressors and oncogenes

CRISPR-Cas9 can also be used to study the role of tumour suppressors and oncogenes. The Kruppel like factor 4 (KLF4) is a transcription factor with varying roles in different tumour sites. Low expression of KLF4 is implicated in bladder cancer progression and promotion of epithelial to mesenchymal transition (EMT)[79]. Conversely, KLF4 overexpression is associated with reduced tumour progression in advanced bladder cancer [80]. CRISPR-mediated KLF4 activation was used to determine the anti-tumour mechanism of KLF4 overexpression in MIBC cells (T24). KLF4 overexpression was shown to suppress T24 cell proliferation through the regulation of AKT—p21 signalling, which induced cell-cycle arrest in the G1 phase. Furthermore, KLF4 activation reduced T24 cell invasion, migration and EMT. The authors from this study concluded that this CRISPR activation system, if translatable to the clinical setting, could act as a novel therapeutic strategy in MIBC [81].

Mounting evidence suggests that epigenetic regulatory proteins have a crucial role as tumour suppressors in diverse types of cancers. *UTX* and its paralog *UTY*, located on the X and Y chromosome, respectively, are histone demethylases that frequently harbour copy number

308 variations and mutations in bladder cancer[82]. These genes have been implicated in tumorigenesis in
309 multiple cancer types through the regulation of proliferation, cell differentiation and metastasis [83,84].
310 In bladder cancer cell lines, CRISPR-Cas9-mediated knock-out was use to silence these epigenetic
311 regulators, either singularly or in combination. This silencing resulted in a substantial increase in cell
312 proliferation, with the most noteworthy effect observed in the double knock-out cells[85]. These results
313 were consistent with results in patient samples from patients undergoing therapy for muscle invasive
314 or high grade bladder cancer, with many patients showing reduced UTX and or UTY copy number and
315 truncating mutations, suggesting a tumour suppressor role of these genes[85]. Moreover, results from
316 this study emphasize the crucial role of X-Y gene pairs in carcinogenesis, particularly in tumour types
317 such as bladder cancer, in which a higher prevalence is reported in male than in female patients [86].
318 Following this study, research focused on assessing whether this loss of function can be targeted
319 therapeutically. *UTX* has a role in antagonizing the enhancer of zeste homolog 2 (EZH2), a
320 methyltransferase involved in histone methylation [87]. Thus, *UTX* knockout has similar effects to EZH2
321 overexpression[87], EZH2 inhibition has been shown to delay tumour onset and suppress tumour
322 growth in xenograft mouse models derived from UTX knockout cell lines as well as patient- derived
323 tumours [87] . These findings suggest that EZH2 inhibition could potentially serve as a novel therapeutic
324 approach for patients with bladder cancer harbouring mutations in *UTX* [88]. However, UTX is a
325 component of the COMPASS family of histone H3K4 methylases. Thus, research into other
326 components of this complex, such as the commonly mutated MLL3 and MLL4 proteins, and their
327 interactions should also be explored, as the role of the COMPASS family in tumorigenesis is not fully
328 understood[89].

329 Other CRISPR systems can be used in different ways. For example, Cas13, an RNA-targeting system,
330 was used to target and degrade the oncogene MYC mRNA, rather than introducing alterations in the
331 gene. Consequently, a decrease in both MYC mRNA and protein expression was achieved, leading to
332 reduced bladder cancer cell proliferation and increased apoptosis [74]. This reduction in protein
333 expression without the need to introduce DNA mutations is advantageous as Cas13 directly targets
334 cytoplasmic mRNA sequences increasing the rate of downregulation of gene expression[90]. These
335 findings introduce a potential targeted therapeutic approach for MIBC. However, these results must
336 be validated in vivo to determine whether this strategy is effective in an organism wide setting.

337 CRISPR-Cas9 can also be used to determine the unknown function of suspected oncogenes or
338 tumour suppressors. Long noncoding RNAs (lncRNAs) have no protein coding ability, but have been
339 implicated in a wide range of cellular functions including pre- and post-transcriptional regulation,
340 epigenetic regulation, and chromosome stability [91]. Interest in the involvement of lncRNAs in cancer
341 is growing, and CRISPR-Cas9 techniques can be used to further elucidate the phenotypic effect of
342 lncRNA manipulations. The lncRNA *SNHG3* has been shown to be implicated in bladder cancer
343 progression, is overexpressed in bladder cancer tumour tissues and is correlated with poor prognosis
344 [92].CRISPR-Cas9 Knockout of SNHG3 in two muscle-invasive bladder cancer cell lines resulted in
345 reduced cell proliferation, migration, invasion, and angiogenesis [92]. SNHG3 was also shown to
346 stabilise B lymphoma Mo-MLV insertion region 1 (BMI1)—through MYC binding—, which inhibits cell
347 senescence and, therefore, is strongly associated with poor prognosis in multiple cancer types [92].
348 These results indicated that targeting the SNHG3—MYC—BMI1 axis could emerge as a promising
349 novel therapeutic target to regulate tumour growth and metastasis in MIBC [92].

350 A crucial component of CRISPR screens is a functional assay to enrich and separate different cell
351 population behaviours. In many instances, this assay can be based on a relatively simple living or
352 death response of cells after a drug or another challenge has been applied. Functional screens can
353 also exploit CRISPR and HDR to create reporter systems, such as knock-in of genes encoding

fluorescent proteins into relevant endogenous loci. This approach creates systems in which cell populations can be separated according to fluorescence intensity that correlates with gene activity. For example, in a 2023 study, knock-in of eGFP into the peroxisome proliferator-activated receptor gamma (*PPARγ*) gene was achieved through CRISPR-Cas9[93]. PPARγ is a transcription factor driving tumour growth, and is known to be upregulated in luminal bladder cancer tumours [93]. In this study[93], following a whole-genome CRISPR screen, cell populations could be sorted according to PPARγ high and low expression, which enabled to identify genes regulating PPARγ expression[93]. Multiple genes were identified and functionally validated as putative positive regulators of PPARγ expression including *GATA3*, *SPT6*, *SMC1A* and *RAD21* [93]. These genes were speculated to be druggable targets for novel luminal bladder cancer therapy [94]. These targets were validated using mRNA expression data from TCGA; however, mRNA expression might not accurately reflect the protein expression and activity of these genes. Additionally, these results were not confirmed using in vivo models, adding further doubt about the possibility to translate these targets into the clinic.

[H1] CRISPR-Cas technology use for gene therapy

CRISPR gene editing shows high promise in the future treatment of cancers, but many factors still prevent the use of these technologies as a direct therapeutic through a gene therapy approach, The main use of CRISPR-Cas gene editing for disease therapy consists in the treatment of monogenic disorders such as sickle cell disease using haematopoietic stem cell transplantation, which have shown high rates of success [95]. In this approach, stem cells are eliminated through chemotherapy before gene therapy, and CRISPR-Cas9 modified stem cells with the mutated gene restored can then be introduced to reconstruct both the blood and immune systems[96]. Cancer derives from multiple genetic mutations that varies between patients, and is far more complex than monogenic disorders. However, CRISPR has been used to improve existing cancer therapies. One example is the chimeric antigen receptor (CAR)-T cell therapy. CAR-T cell therapy has showed efficacy in treating acute lymphoblastic leukaemia, but the need of using patients' own CAR-T cells can lead to treatment delays. To overcome this obstacle, CRISPR-Cas9 was used to modify CAR-T cells targeting CD19 and CD22. This modification involved disrupting the TRAC region and CD52 gene to prevent immune rejection. The resulting edited CAR-T cells were subsequently introduced into patients, resulting in favourable anti-cancer responses and minimal adverse effects. [97].

These CRISPR-mediated therapies have shown success in haematological malignancies, but the translation of these therapies to solid tumours, such as bladder cancer, has been a challenging task. However, promising advances have been obtained in pre-clinical studies targeting solid tumours. An emerging therapeutic strategy based on T cells targeting solid tumours is the T-cell receptor (TCR) therapy. TCR therapy involves the use of genetically modified T cells engineered to recognise tumour-specific markers [98]. This strategy should provide therapeutic benefit without causing damage to normal cells. The efficacy of TCR therapy was initially shown in xenograft tumours derived from patients, prompting clinical trials to evaluate the potential of this innovative treatment approach in a variety of tumours including lung cancer, renal cell carcinoma and gastrointestinal cancers with varying levels of success [99, 100]. In a 2023 study, patient-specific TCR therapy was generated using patient's peripheral blood mononuclear cells (PBMCs) from patients with a variety of solid tumours [101]. This approach enabled to compare germline and tumour DNA to identify each patient's specific tumour mutations. Subsequently, CRISPR-Cas9 gene editing was used to create genetically modified T cells with neoantigens designed to target the tumour[102]. This result was achieved through knockout of the endogenous *TRAC* and *TRBC* genes and introduction of engineered neoantigen-specific TCRs [102]. These sequences were cloned into DNA plasmids designed for homologous recombination with the endogenous TRAC site on the DNA, prompting the neoantigen's expression on the T cell surface.

400 These genetically altered T cells were then reintroduced into the patient [102]. Notably, these cells
401 successfully localized to the tumour sites. Encouragingly, some patients showed disease stabilization
402 or even a reduction in tumour size 28 days after the T cell infusion [102]. This outcome is relevant, as
403 these patients had refractory cancers and had already undergone six rounds of previous therapies.
404 Results from this study indicated the safety of infusing transgenic T cells into patients and suggested
405 the potential therapeutic value of these modified cells in diminishing tumour size in a wide range of
406 solid tumours. CAR T cell therapy shows high potency and rapid tumour killing within shorter
407 timeframes than TCR, but an inverse relationship is observed between CAR T cell proliferation and
408 increased target antigen expression[103], which diminishes the effectiveness of tumour targeting.
409 Conversely, TCR cell therapy showed high proliferation also in high antigen environments, sustaining
410 efficient rates of tumour clearance [103]. This evidence suggests that TCR cell therapy in combination
411 with CRISPR-Cas9-based gene modifications might held good performance across a broader
412 spectrum of tumour antigen presentations than CAR T [104].

413 A crucial issue in drug efficacy is the infiltration of the extracellular matrix (ECM) to target tumour
414 cells. In one study in 5A2-SC8 liver cells, this issue was overcome using liquid nanoparticles to co-
415 deliver siRNA targeting focal adhesion kinases to break down the ECM alongside Cas9 mRNA and a
416 sgRNA targeting PDL1 [105]. The introduction of siRNA targeting focal adhesion kinases decreased the
417 ECM, resulting in two important outcomes: a tenfold enhancement in CRISPR-mediated gene editing
418 within tumour in in vitro spheroid models; and increased infiltration of immune cells, contributing to
419 decreased tumour growth during in vivo mouse experiments[105]. These results are encouraging and
420 show potential for the development of innovative CRISPR-Cas9-based therapies for solid tumours,
421 with potential applicability also in bladder cancer.

422 Multiple clinical trials using CRISPR-based therapeutics are ongoing. For example, there is a phase I/II
423 trial currently recruiting patients with metastatic gastrointestinal epithelial cancer for treatment with
424 neoantigen specific tumour infiltrating lymphocytes CRISPR Cas9 genetically edited to inhibit the
425 intracellular immune checkpoint CISH [106]. Another ongoing phase I/II trial is investigating the safety
426 and efficacy of CRISPR-Cas9 edited CAR T cells in patients with refractory solid tumours [107].
427 However, these trials are still in very early stages, with a high focus on dosage and safety of
428 treatments. Additional research is required before these treatments are available for widespread use
429 in the clinic. However, advances in the translation of these therapies in solid tumours provides hope
430 about the possibility of using gene editing-based therapies to treat bladder tumours. The design of
431 TCR therapies based on individual tumour neoantigens could be of high importance in bladder
432 cancer, in which the high tumour heterogeneity remains a substantial problem. Bladder tumours
433 have high tumour mutational burden (TMB) and, therefore, are ideal candidates for TCR therapies, as
434 higher the TMB the more neo-antigens are available for targeting, leading to increased therapeutic
435 success [108].

436 **[H1] Limitations and ethical considerations**

437 An important limitation of CRISPR screening in cancer research is that most current studies have
438 been completed in vitro but not in vivo. CRISPR-Cas9 screens have shown to be an invaluable
439 resource in uncovering potential therapeutic targets, but translating these findings into the clinic is
440 crucial. Thus, advancements in generation and ease of access of in vivo-based CRISPR-Cas9
441 methodologies are required to validate the findings of CRISPR screens and accelerate the future use
442 of CRISPR-Cas9-based therapies into the clinic. These in vivo models could include animal models
443 and tumour xenografts, as well as the development of conditional tissue-specific knockouts to study
444 gene functions at a tissue-specific level.

With regards to the development of CRISPR-based therapeutics, the safe delivery of CRISPR into patients remains a substantial challenge. These therapies need to target tumour cells specifically, without inducing death of normal cells and off-target effects, which is a major aspect to consider for the translation of CRISPR into the clinic[109]. Off-target effects could have catastrophic consequences including induction of novel oncogenic mutations. Results from current pre-clinical and clinical trials in which CRISPR-Cas9 based therapeutics have been used have shown that off-target effects are rare, indicating that CRISPR-Cas9-mediated gene editing is highly targeted, and holds promise in large-scale clinical trials of these therapies [110]. The identification of off target effects has been enhanced through the development of GUIDE-seq. GUIDE-seq identifies where DSBs have occurred and through the detection of double-stranded oligodeoxynucleotides, which enables us to conduct genome-wide profiling of CRISPR-induced off-target effects [111].

For example, the use of these technologies in the treatment of Sickle-cell disease is relatively simple, as delivery of CRISPR components occurs ex vivo as HPSCs are extracted, edited and reintroduced into the patient[95]. A crucial issue in the delivery of gene editing in situ is the targetability of the desired tissue or organ. The liver, for example, has proven to be a targetable organ via lipid nanoparticle-based delivery systems for the treatment of transthyretin amyloidosis[112]. For bladder cancer, the challenge remains how to target cells in situ [113,114]. Only when methods to facilitate the delivery of CRISPR-Cas based therapeutics into the bladder cancer cells avoiding off-target effects will be developed, rapid advancements in the use of CRISPR-based strategies in MIBC treatment will be possible.

Ethical considerations are also associated with the use of CRISPR-Cas gene editing in clinical therapies. Considerations range from somatic cell gene editing as well as use of exogenous transfer of CRISPR-edited cells into patients .As these technologies are still in their infancy there is limited long term effect data limiting the justification for the widespread use of these CRISPR-Cas based therapeutics. [115]. Ethical considerations are reduced considering the use of an individual's genetically altered cells, as only the patient would be affected, whereas germline gene editing could also affect future generations [116]. Lastly, the long-term implications of CRISPR-Cas9 editing in humans are not fully understood. Thus, the use of these technologies must be tightly regulated to ensure patient safety.

[H1] Conclusions

CRISPR-Cas9 gene editing techniques have provided a vast amount of knowledge in MIBC research, from the identification of drug resistance mechanisms to novel drug targets. However, the use of these technologies into the clinic as a gene-therapy approach remains a substantial challenge. The current use of CRISPR-Cas9 gene editing in the treatment of monogenic disorders is encouraging for future perspectives in cancer treatments. Currently, the area of CRISPR-based therapies showing most promise in the treatment of solid tumours in clinical trials is the use of genetically engineered patient-derived T cells to recognise tumour neoantigens. This area of research highlights how CRISPR technologies could advance the field of immunotherapies and personalised medicine in cancer research.

However, the use of CRISPR technologies for the treatment of baldder cancer into clinical settings will require careful evaluation of dosage and safety. The greatest challenges in this area concern off-target effects, ethical implications of somatic cell gene editing, and the unknown long-term outcomes of CRISPR-Cas9-related therapeutics.

488 CRISPR-Cas9 offers considerable potential for revolutionizing bladder cancer therapies, but
489 substantial research into validation of these technologies is required before achieving wide use in the
490 clinical setting. The intricate genetic landscape of MIBC shows the need for a multidisciplinary
491 treatment approach, and continued research will be required to use the full potential of CRISPR-
492 based technologies in the development of novel precision therapeutics.

493 **References [Au: please check and update the references as necessary]**

494 1. Gaj, T., Gersbach, C. A. & Barbas, C. F. ZFN, TALEN, and CRISPR/Cas-based methods for
495 genome engineering. *Trends in Biotechnology* vol. 31 Preprint at
496 https://doi.org/10.1016/j.tibtech.2013.04.004 (2013).

497 2. Xiao-Jie, L., Hui-Ying, X., Zun-Ping, K., Jin-Lian, C. & Li-Juan, J. CRISPR-Cas9: A new and
498 promising player in gene therapy. *J Med Genet* **52**, (2015).

499 3. Awwad, S. W., Serrano-Benitez, A., Thomas, J. C., Gupta, V. & Jackson, S. P.
500 Revolutionizing DNA repair research and cancer therapy with CRISPR–Cas screens.
501 *Nature Reviews Molecular Cell Biology* vol. 24 Preprint at
502 https://doi.org/10.1038/s41580-022-00571-x (2023).

503 4. Wang, M., Chen, M., Wu, X., Huang, X. & Yu, B. CRISPR applications in cancer diagnosis
504 and treatment. *Cellular and Molecular Biology Letters* vol. 28 Preprint at
505 https://doi.org/10.1186/s11658-023-00483-4 (2023).

506 5. Das, S., Bano, S., Kapse, P. & Kundu, G. C. CRISPR based therapeutics: a new paradigm
507 in cancer precision medicine. *Molecular Cancer* vol. 21 Preprint at
508 https://doi.org/10.1186/s12943-022-01552-6 (2022).

509 6. CRUK, Bladder cancer incidence statistics, UK, new cases each year 2016-2018, both
510 sexes, all ages. https://www.cancerresearchuk.org/health-professional/cancer-
511 statistics/statistics-by-cancer-type/bladder-cancer/incidence.

512 7. Chang, S. S. *et al.* Diagnosis and Treatment of Non-Muscle Invasive Bladder Cancer:
513 AUA/SUO Guideline. *Journal of Urology* **196**, (2016).

514 8. Cancer survival in England. *Office for national statistics* (2019).

515 9. Nadal, R. & Bellmunt, J. Management of metastatic bladder cancer. *Cancer Treatment*
516 *Reviews* vol. 76 Preprint at https://doi.org/10.1016/j.ctrv.2019.04.002 (2019).

517 10. Perera, J. & Hoskin, P. The role of radiotherapy in metastatic bladder cancer. *Journal of*
518 *Cancer Metastasis and Treatment* vol. 8 Preprint at https://doi.org/10.20517/2394-
519 4722.2021.167 (2022).

520 11. Song, Y. P. *et al.* Long-Term Outcomes of Radical Radiation Therapy with Hypoxia
521 Modification with Biomarker Discovery for Stratification: 10-Year Update of the BCON
522 (Bladder Carbogen Nicotinamide) Phase 3 Randomized Trial (ISRCTN45938399). *Int J*
523 *Radiat Oncol Biol Phys* **110**, 1407–1415 (2021).

524 12. Rhea, L. P., Mendez-Marti, S., Kim, D. & Aragon-Ching, J. B. Role of immunotherapy in
525 bladder cancer. *Cancer Treatment and Research Communications* vol. 26 Preprint at
526 https://doi.org/10.1016/j.ctarc.2020.100296 (2021).

527 13. Stenehjem, D. D., Tran, D., Nkrumah, M. A. & Gupta, S. PD1/PDL1 inhibitors for the
528 treatment of advanced urothelial bladder cancer. *OncoTargets and Therapy* vol. 11
529 Preprint at https://doi.org/10.2147/OTT.S135157 (2018).

530 14. Lopez-Beltran, A. *et al.* Immune checkpoint inhibitors for the treatment of bladder
531 cancer. *Cancers* vol. 13 Preprint at https://doi.org/10.3390/cancers13010131 (2021).

532 15. Massari, F. *et al.* Immune checkpoint inhibitors for metastatic bladder cancer. *Cancer*
533 *Treatment Reviews* vol. 64 Preprint at https://doi.org/10.1016/j.ctrv.2017.12.007
534 (2018).

535 16. Fong, M. H. Y., Feng, M., McConkey, D. J. & Choi, W. Update on bladder cancer
536 molecular subtypes. *Transl Androl Urol* **9**, (2020).

537 17. McConkey, D. J. & Choi, W. Molecular Subtypes of Bladder Cancer. *Current Oncology*
538 *Reports* vol. 20 Preprint at https://doi.org/10.1007/s11912-018-0727-5 (2018).

539 18. Kamoun, A. *et al.* A Consensus Molecular Classification of Muscle-invasive Bladder
540 Cancer[Formula presented]. *Eur Urol* **77**, (2020).

541 19. Marraffini, L. A. *The CRISPR-Cas System of Streptococcus Pyogenes: Function and*
542 *Applications*. *Streptococcus pyogenes : Basic Biology to Clinical Manifestations* (2016).

543 20. Doudna, J. A. & Charpentier, E. The new frontier of genome engineering with CRISPR-
544 Cas9. *Science* vol. 346 Preprint at https://doi.org/10.1126/science.1258096 (2014).

545 21. Hsu, P. D., Lander, E. S. & Zhang, F. Development and applications of CRISPR-Cas9 for
546 genome engineering. *Cell* vol. 157 Preprint at
547 https://doi.org/10.1016/j.cell.2014.05.010 (2014).

548 22. Gunitseva, N., Evteeva, M., Borisova, A., Patrushev, M. & Subach, F. RNA-Dependent
549 RNA Targeting by CRISPR-Cas Systems: Characterizations and Applications.
550 *International Journal of Molecular Sciences* vol. 24 Preprint at
551 https://doi.org/10.3390/ijms24086894 (2023).

552 23. Pickar-Oliver, A. & Gersbach, C. A. The next generation of CRISPR–Cas technologies and
553 applications. *Nature Reviews Molecular Cell Biology* vol. 20 Preprint at
554 https://doi.org/10.1038/s41580-019-0131-5 (2019).

555 24. Hefferin, M. L. & Tomkinson, A. E. Mechanism of DNA double-strand break repair by
556 non-homologous end joining. *DNA Repair* vol. 4 Preprint at
557 https://doi.org/10.1016/j.dnarep.2004.12.005 (2005).

558 25. Chu, V. T. *et al.* Increasing the efficiency of homology-directed repair for CRISPR-Cas9-
559 induced precise gene editing in mammalian cells. *Nat Biotechnol* **33**, (2015).

560 26. Scully, R., Panday, A., Elango, R. & Willis, N. A. DNA double-strand break repair-
561 pathway choice in somatic mammalian cells. *Nature Reviews Molecular Cell Biology*
562 vol. 20 Preprint at https://doi.org/10.1038/s41580-019-0152-0 (2019).

563 27. Jensen, T. I. *et al.* Targeted regulation of transcription in primary cells using CRISPRa
564 and CRISPRi. *Genome Res* **31**, (2021).

565 28. Maeder, M. L. *et al.* CRISPR RNA-guided activation of endogenous human genes. *Nat*
566 *Methods* **10**, (2013).

567 29. Armando Casas-Mollano, J., Zinselmeier, M. H., Erickson, S. E. & Smanski, M. J. CRISPR-
568 Cas Activators for Engineering Gene Expression in Higher Eukaryotes. *CRISPR Journal*
569 vol. 3 Preprint at https://doi.org/10.1089/crispr.2020.0064 (2020).

570 30. Larson, M. H. *et al.* CRISPR interference (CRISPRi) for sequence-specific control of gene
571 expression. *Nat Protoc* **8**, (2013).

572 31. Gilbert Luke A *et al.* CRISPR-mediated modular RNA-guided regulation of transcription
573 in eukaryotes. *Cell* **154**, (2013).

574 32. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a
575 target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**,
576 (2016).

577 33. Gaudelli, N. M. *et al.* Programmable base editing of T to G C in genomic DNA without
578 DNA cleavage. *Nature* **551**, (2017).

579 34. Komor, A. C., Kim, Y. B., Packer, M. S., Zuris, J. A. & Liu, D. R. Programmable editing of a
580 target base in genomic DNA without double-stranded DNA cleavage. *Nature* **533**,
581 (2016).

582 35. Gaudelli, N. M. *et al.* Programmable base editing of T to G C in genomic DNA without
583 DNA cleavage. *Nature* **551**, (2017).

584 36. Eid, A., Alshareef, S. & Mahfouz, M. M. CRISPR base editors: Genome editing without
585 double-stranded breaks. *Biochemical Journal* vol. 475 Preprint at
586 https://doi.org/10.1042/BCJ20170793 (2018).

587 37. Anzalone, A. V. *et al.* Search-and-replace genome editing without double-strand breaks
588 or donor DNA. *Nature* **576**, (2019).

589 38. Nelson, J. W. *et al.* Engineered pegRNAs improve prime editing efficiency. *Nat*
590 *Biotechnol* **40**, (2022).

591 39. Mali, P. *et al.* RNA-guided human genome engineering via Cas9. *Science (1979)* **339**,
592 (2013).

593 40. Wang, T., Wei, J. J., Sabatini, D. M. & Lander, E. S. Genetic screens in human cells using
594 the CRISPR-Cas9 system. *Science (1979)* **343**, (2014).

595 41. Li, W. *et al.* MAGeCK enables robust identification of essential genes from genome-
596 scale CRISPR/Cas9 knockout screens. *Genome Biol* **15**, (2014).

597 42. Zetsche, B. *et al.* Cpf1 Is a Single RNA-Guided Endonuclease of a Class 2 CRISPR-Cas
598 System. *Cell* **163**, (2015).

599 43. Zhang, C. *et al.* Structural Basis for the RNA-Guided Ribonuclease Activity of CRISPR-
600 Cas13d. *Cell* **175**, (2018).

601 44. Gao, Y. *et al.* Complex transcriptional modulation with orthogonal and inducible dCas9
602 regulators. *Nat Methods* **13**, (2016).

603 45. Liu, J. *et al.* C A N C E R Delivery of RIPK4 small interfering RNA for bladder cancer
604 therapy using natural halloysite nanotubes. *Sci Adv* **5**, (2019).

605 46. Chen, S. H. & Zhaori, G. Potential clinical applications of siRNA technique: Benefits and
606 limitations. *European Journal of Clinical Investigation* vol. 41 Preprint at
607 https://doi.org/10.1111/j.1365-2362.2010.02400.x (2011).

608 47. Isazadeh, H. *et al.* Advances in siRNA delivery approaches in cancer therapy:
609 challenges and opportunities. *Molecular Biology Reports* vol. 50 Preprint at
610 https://doi.org/10.1007/s11033-023-08749-y (2023).

611 48. Massari, F. *et al.* Emerging concepts on drug resistance in bladder cancer: Implications
612 for future strategies. *Critical Reviews in Oncology/Hematology* vol. 96 Preprint at
613 https://doi.org/10.1016/j.critrevonc.2015.05.005 (2015).

614 49. Galluzzi, L. *et al.* Molecular mechanisms of cisplatin resistance. *Oncogene* vol. 31
615 Preprint at https://doi.org/10.1038/onc.2011.384 (2012).

616 50. Yu, H. M. & Wang, T. C. Mechanism of cisplatin resistance in human urothelial
617 carcinoma cells. *Food and Chemical Toxicology* **50**, (2012).

618 51. Liu, S., Chen, X. & Lin, T. Emerging strategies for the improvement of chemotherapy in
619 bladder cancer: Current knowledge and future perspectives. *Journal of Advanced*
620 *Research* vol. 39 Preprint at https://doi.org/10.1016/j.jare.2021.11.010 (2022).

621 52. Kumar, G. *et al.* Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of
622 cisplatin sensitivity in muscle-invasive bladder cancer. *Urologic Oncology: Seminars*
623 *and Original Investigations* **38**, (2020).

624 53. Kumar, G. *et al.* Genome-wide CRISPR screen reveals SLFN11 as a potent mediator of
625 cisplatin sensitivity in muscle-invasive bladder cancer. *Urologic Oncology: Seminars*
626 *and Original Investigations* **38**, (2020).

627 54. Luan, J., Gao, X., Hu, F., Zhang, Y. & Gou, X. SLFN11 is a general target for enhancing
628 the sensitivity of cancer to chemotherapy (DNA-damaging agents). *Journal of Drug*
629 *Targeting* vol. 28 Preprint at https://doi.org/10.1080/1061186X.2019.1616746 (2020).

630 55. Zhang, B. *et al.* A wake-up call for cancer DNA damage: the role of Schlafen 11
631 (SLFN11) across multiple cancers. *British Journal of Cancer* vol. 125 Preprint at
632 https://doi.org/10.1038/s41416-021-01476-w (2021).

633 56. Mohammad, H. P., Barbash, O. & Creasy, C. L. Targeting epigenetic modifications in
634 cancer therapy: erasing the roadmap to cancer. *Nature Medicine* vol. 25 Preprint at
635 https://doi.org/10.1038/s41591-019-0376-8 (2019).

636 57. Goodspeed, A., Jean, A. & Costello, J. C. A Whole-genome CRISPR Screen Identifies a
637 Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. *Eur*
638 *Urol* **75**, (2019).

639 58. Lan, L. *et al.* Functional and physical interactions between ERCC1 and MSH2 complexes
640 for resistance to cis-diamminedichloroplatinum(II) in mammalian cells. *DNA Repair*
641 *(Amst)* **3**, (2004).

642 59. Goodspeed, A., Jean, A. & Costello, J. C. A Whole-genome CRISPR Screen Identifies a
643 Role of MSH2 in Cisplatin-mediated Cell Death in Muscle-invasive Bladder Cancer. *Eur*
644 *Urol* **75**, (2019).

645 60. Zhang, H. *et al.* CircLIFR synergizes with MSH2 to attenuate chemoresistance via
646 MutSα/ATM-p73 axis in bladder cancer. *Mol Cancer* **20**, (2021).

647 61. Shi, Z. duo *et al.* Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
648 *Mol Cancer* **21**, (2022).

649 62. Shi, Z. duo *et al.* Targeting HNRNPU to overcome cisplatin resistance in bladder cancer.
650 *Mol Cancer* **21**, (2022).

651 63. Hoskin, P. J. *et al.* Carbogen and nicotinamide in the treatment of bladder cancer with
652 radical radiotherapy. *Br J Cancer* **76**, (1997).

653 64. Hoskin, P. J., Rojas, A. M., Bentzen, S. M. & Saunders, M. I. Radiotherapy with
654 concurrent carbogen and nicotinamide in bladder carcinoma. *Journal of Clinical*
655 *Oncology* **28**, (2010).

656 65. Rhea, L. P., Mendez-Marti, S., Kim, D. & Aragon-Ching, J. B. Role of immunotherapy in
657 bladder cancer. *Cancer Treatment and Research Communications* vol. 26 Preprint at
658 https://doi.org/10.1016/j.ctarc.2020.100296 (2021).

659 66. Galsky, M. D. *et al.* Gemcitabine and cisplatin plus nivolumab as organ-sparing
660 treatment for muscle-invasive bladder cancer: a phase 2 trial. *Nat Med* (2023)
661 doi:10.1038/s41591-023-02568-1.

662 67. Zhang, W. *et al.* Disruption of CTLA-4 expression on peripheral blood CD8 + T cell
663 enhances anti-tumor efficacy in bladder cancer. *Cancer Chemother Pharmacol* (2019)
664 doi:10.1007/s00280-019-03800-x.

665 68. Zhen, S., Lu, J., Chen, W., Zhao, L. & Li, X. Synergistic Antitumor Effect on Bladder
666 Cancer by Rational Combination of Programmed Cell Death 1 Blockade and CRISPR-
667 Cas9-Mediated Long Non-Coding RNA Urothelial Carcinoma Associated 1 Knockout.
668 *Hum Gene Ther* **29**, (2018).

669 69. Zhen, S. *et al.* Inhibition of long non-coding RNA UCA1 by CRISPR/Cas9 attenuated
670 malignant phenotypes of bladder cancer. *Oncotarget* **8**, (2017).

671 70. Nandwani, A., Rathore, S. & Datta, M. LncRNAs in cancer: Regulatory and therapeutic
672 implications. *Cancer Letters* vol. 501 Preprint at
673 https://doi.org/10.1016/j.canlet.2020.11.048 (2021).

674 71. He, Z. X. *et al.* Current development of CBP/p300 inhibitors in the last decade.
675 *European Journal of Medicinal Chemistry* vol. 209 Preprint at
676 https://doi.org/10.1016/j.ejmech.2020.112861 (2021).

677 72. Liu, Y. *et al.* Synthesizing and gate genetic circuits based on CRISPR-Cas9 for
678 identification of bladder cancer cells. *Nat Commun* **5**, (2014).

679 73. Li, J. *et al.* A CRISPR interference of CBP and p300 selectively induced synthetic
680 lethality in bladder cancer cells in vitro. *Int J Biol Sci* **15**, (2019).

74. Zhuang, C. *et al.* Engineered CRISPR/Cas13d Sensing hTERT Selectively Inhibits the Progression of Bladder Cancer In Vitro. *Front Mol Biosci* **8**, (2021).

75. Zhang, M. *et al.* CDK inhibitors in cancer therapy, an overview of recent development. *Am J Cancer Res* **11**, (2021).

76. Rose, T. L. *et al.* Phase II trial of palbociclib in patients with metastatic urothelial cancer after failure of first-line chemotherapy. *Br J Cancer* **119**, (2018).

77. Tong, Z. *et al.* Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. *Journal of Experimental and Clinical Cancer Research* **38**, (2019).

78. Tong, Z. *et al.* Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer. *Journal of Experimental and Clinical Cancer Research* **38**, (2019).

79. He, Z., He, J. & Xie, K. KLF4 transcription factor in tumorigenesis. *Cell Death Discovery 2023 9:1* **9**, 1–13 (2023).

80. He, Z., He, J. & Xie, K. KLF4 transcription factor in tumorigenesis. *Cell Death Discovery 2023 9:1* **9**, 1–13 (2023).

81. Xu, X. *et al.* CRISPR-ON-Mediated KLF4 overexpression inhibits the proliferation, migration and invasion of urothelial bladder cancer in vitro and in vivo. *Oncotarget* **8**, (2017).

82. Chen, L. J. *et al.* The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. *Bioorganic Chemistry* vol. 133 Preprint at https://doi.org/10.1016/j.bioorg.2023.106409 (2023).

83. Chen, L. J. *et al.* The role of lysine-specific demethylase 6A (KDM6A) in tumorigenesis and its therapeutic potentials in cancer therapy. *Bioorganic Chemistry* vol. 133 Preprint at https://doi.org/10.1016/j.bioorg.2023.106409 (2023).

84. Matar, M. *et al.* Implication of KDM6A in bladder cancer. *Pharmacogenomics* vol. 24 Preprint at https://doi.org/10.2217/pgs-2023-0027 (2023).

85. Ahn, J. *et al.* Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer. *Oncotarget* **7**, (2016).

86. Ahn, J. *et al.* Target sequencing and CRISPR/Cas editing reveal simultaneous loss of UTX and UTY in urothelial bladder cancer. *Oncotarget* **7**, (2016).

87. Ler, L. D. *et al.* Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. *Sci Transl Med* **9**, (2017).

88. Ler, L. D. *et al.* Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2. *Sci Transl Med* **9**, (2017).

89. Lang, A. *et al.* Contingencies of UTX/KDM6A action in urothelial carcinoma. *Cancers (Basel)* **11**, (2019).

90. Hillary, V. E. & Ceasar, S. A. A Review on the Mechanism and Applications of CRISPR/Cas9/Cas12/Cas13/Cas14 Proteins Utilized for Genome Engineering. *Molecular Biotechnology* vol. 65 Preprint at https://doi.org/10.1007/s12033-022-00567-0 (2023).

91. Zhang, R., Xia, L. Q., Lu, W. W., Zhang, J. & Zhu, J. S. LncRNAs and cancer. *Oncology Letters* vol. 12 Preprint at https://doi.org/10.3892/ol.2016.4770 (2016).

92. Xie, J. *et al.* LncRNA SNHG3 enhances BMI1 mRNA stability by binding and regulating c-MYC: Implications for the carcinogenic role of SNHG3 in bladder cancer. *Cancer Med* **12**, (2023).

93. Tortora, D. *et al.* A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. *iScience* **26**, 106525 (2023).

94. Tortora, D. *et al.* A genome-wide CRISPR screen maps endogenous regulators of PPARG gene expression in bladder cancer. *iScience* **26**, 106525 (2023).

95. Frangoul, H. *et al.* Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. *Blood* **136**, (2020).

96. Frangoul, H. *et al.* Safety and Efficacy of CTX001 in Patients with Transfusion-Dependent β-Thalassemia and Sickle Cell Disease: Early Results from the Climb THAL-111 and Climb SCD-121 Studies of Autologous CRISPR-CAS9-Modified CD34+ Hematopoietic Stem and Progenitor Cells. *Blood* **136**, (2020).

97. Hu, Y. *et al.* CRISPR/Cas9-engineered universal CD19/CD22 dual-targeted CAR-T cell therapy for relapsed/refractory B-cell acute lymphoblastic leukemia. *Clinical Cancer Research* **27**, (2021).

98. Tsimberidou, A. M. *et al.* T-cell receptor-based therapy: an innovative therapeutic approach for solid tumors. *Journal of Hematology and Oncology* vol. 14 Preprint at https://doi.org/10.1186/s13045-021-01115-0 (2021).

99. Tan, E., Gakhar, N. & Kirtane, K. TCR gene-engineered cell therapy for solid tumors. *Best Practice and Research: Clinical Haematology* vol. 34 Preprint at https://doi.org/10.1016/j.beha.2021.101285 (2021).

100. He, J. *et al.* Defined tumor antigen-specific T cells potentiate personalized TCR-T cell therapy and prediction of immunotherapy response. *Cell Res* **32**, (2022).

101. Foy, S. P. *et al.* Non-viral precision T cell receptor replacement for personalized cell therapy. *Nature* **615**, (2023).

102. Foy, S. P. *et al.* Non-viral precision T cell receptor replacement for personalized cell therapy. *Nature* **615**, (2023).

103. Wachsmann, T. L. A. *et al.* Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. *Oncoimmunology* **11**, (2022).

104. Wachsmann, T. L. A. *et al.* Comparing CAR and TCR engineered T cell performance as a function of tumor cell exposure. *Oncoimmunology* **11**, (2022).

759 105. Zhang, D. *et al.* Enhancing CRISPR/Cas gene editing through modulating cellular
760 mechanical properties for cancer therapy. *Nat Nanotechnol* **17**, (2022).

761 106. US National Library of Medicine. ClinicalTrials.gov (2023).
762 https://clinicaltrials.gov/study/NCT04426669.

763 107. US National Library of Medicine. ClinicalTrials.gov (2023).

764 108. Jardim, D. L., Goodman, A., de Melo Gagliato, D. & Kurzrock, R. The Challenges of
765 Tumor Mutational Burden as an Immunotherapy Biomarker. *Cancer Cell* vol. 39
766 Preprint at https://doi.org/10.1016/j.ccell.2020.10.001 (2021).

767 109. Yang, Y., Xu, J., Ge, S. & Lai, L. CRISPR/Cas: Advances, Limitations, and Applications for
768 Precision Cancer Research. *Frontiers in Medicine* vol. 8 Preprint at
769 https://doi.org/10.3389/fmed.2021.649896 (2021).

770 110. Wang, S. W. *et al.* Current applications and future perspective of CRISPR/Cas9 gene
771 editing in cancer. *Molecular Cancer* vol. 21 Preprint at https://doi.org/10.1186/s12943-
772 022-01518-8 (2022).

773 111. Tsai, S. Q. *et al.* GUIDE-seq enables genome-wide profiling of off-target cleavage by
774 CRISPR-Cas nucleases. *Nat Biotechnol* **33**, (2015).

775 112. Gillmore, J. D. *et al.* CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
776 *New England Journal of Medicine* **385**, (2021).

777 113. Aimo, A. *et al.* RNA-targeting and gene editing therapies for transthyretin amyloidosis.
778 *Nature Reviews Cardiology* vol. 19 Preprint at https://doi.org/10.1038/s41569-022-
779 00683-z (2022).

780 114. Gillmore, J. D. *et al.* CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
781 *New England Journal of Medicine* **385**, (2021).

782 115. Sýkora, P. Chapter 11 Germline Gene Therapy in the Era of Precise Genome Editing:
783 How Far Should We Go? in *Philosophy and Medicine* vol. 128 (2018).

784 116. Brokowski, C. & Adli, M. CRISPR Ethics: Moral Considerations for Applications of a
785 Powerful Tool. *Journal of Molecular Biology* vol. 431 Preprint at
786 https://doi.org/10.1016/j.jmb.2018.05.044 (2019).

787 117. Dang, Y. *et al.* Optimizing sgRNA structure to improve CRISPR-Cas9 knockout efficiency.
788 *Genome Biol* **16**, (2015).

789 118. Sternberg, S. H., Redding, S., Jinek, M., Greene, E. C. & Doudna, J. A. DNA interrogation
790 by the CRISPR RNA-guided endonuclease Cas9. *Nature* **507**, (2014).

791 119. Gong, S., Yu, H. H., Johnson, K. A. & Taylor, D. W. DNA Unwinding Is the Primary
792 Determinant of CRISPR-Cas9 Activity. *Cell Rep* **22**, (2018).

793 120. Ran, F. A. *et al.* Genome engineering using the CRISPR-Cas9 system. *Nat Protoc* **8**,
794 (2013).

795 121. Jiang, F. & Doudna, J. A. CRISPR-Cas9 Structures and Mechanisms. *Annual Review of*
796 *Biophysics* vol. 46 Preprint at https://doi.org/10.1146/annurev-biophys-062215-
797 010822 (2017).

798 122. Liang, F., Han, M., Romanienko, P. J. & Jasin, M. Homology-directed repair is a major
799 double-strand break repair pathway in mammalian cells. *Proc Natl Acad Sci U S A* **95**,
800 (1998).

801 123. Lino, C. A., Harper, J. C., Carney, J. P. & Timlin, J. A. Delivering crispr: A review of the
802 challenges and approaches. *Drug Delivery* vol. 25 Preprint at
803 https://doi.org/10.1080/10717544.2018.1474964 (2018).

804

805 The authors declare no competing interests.

806 **Author contributions**

807 D.J.S. researched data for the article. D.J.S. contributed substantially to discussion of the content. D.J.S. wrote the article. S.L., A.A., S.N.,
808 T.S.,K.R., P.H. and A.C. reviewed and/or edited the manuscript before submission.

809

810 **Box1**

CRISPR-Cas9 system

The CRISPR-Cas9 system induces double-strand breaks (DSBs) in DNA using the Cas9 endonuclease bound to a single-guide RNA molecule (sgRNA), which guides the Cas9 to the DNA target site. The sgRNA molecule consists of two parts, a trans-activating CRISPR RNA (tracrRNA) and a user-defined CRISPR RNA (crRNA), which is complementary to the target region of the genome. A pre-requisite for DNA targeting is a protospacer adjacent motif (PAM) site, a 2–6 nucleotide DNA sequence that must be located adjacent to the target sequence, and is necessary for Cas9 to bind the cleavage site[117]. Even one-nucleotide change within the PAM site has been shown to prevent Cas9 binding [118]. Upon sgRNA binding to the target DNA following PAM site recognition, the DNA unwinds, and a DNA:RNA hybrid R-loop structure is formed between sgRNA and the target DNA strand, whereas the non-target DNA strand is displaced [119]. If the DNA and RNA sequences match, the target DNA will continue to unwind until the whole crRNA has successfully bound. This binding causes a conformational change of Cas9 to the active state that can recognise and bind DNA. Cas9 has two nuclease domains, HNH and RuvC, each responsible for the cleavage of opposite DNA strands [120,121]. The formation of the R-loop enables the Cas9 nuclease domains to access and cleave the individual strands, inducing a double-strand break (DSB). Following DSB, DNA-repair pathways are activated. The most commonly used repair mechanism is non-homologous end joining (NHEJ), which, however, is highly error prone, because an intact homologous DNA strand is not used as a template, and often results in insertions or deletions in the genome. In coding regions of the genome, these modifications can result into frameshift mutations and premature stop codons, leading to amino acid changes[24]. The alternative and less common mechanism of DNA repair following a Cas9-induced DSB is homology-directed repair (HDR), which requires a homologous DNA sequence as a template to repair the original DNA [122]. This homologous sequence could be supplied exogenously or could be from a sister chromatid [123]. This mechanism is highly precise and can be used to induce mutations of choice within the DNA by including these mutations into the homologous template DNA [25].

811

812 **Figure 1. CRISPR-Cas9 mechanism and alternative methodologies**

813 **a)** Single-guide RNA (sgRNA) complexed with Cas9 binds to the DNA inducing a double-strand break
814 (DSB), which is subsequently repaired through different DNA-repair mechanisms, including non-
815 homologous end joining (NHEJ) and homology directed repair (HDR). NHEJ is error prone, resulting in

indels in the DNA sequence, whereas HDR accurately repairs the DNA, as a homologous DNA repair strand is required. **b)** CRISPR activation (CRISPRa). A catalytically dead Cas9 (dCas9) bound to a transcriptional activator and sgRNA induces transcriptional activation of target genes. **c)** CRISPR interference (CRISPRi). dCas9 bound to a transcriptional repressor and sgRNA inhibits transcription of target genes. **d)** Base editor. dCas9 bound to deaminase and sgRNA removes an amino acid from a nucleoside inducing a single-nucleotide polymorphism. **e)** Prime editor. A Cas9 nickase is bound to a prime editing guide RNA (pegRNA) and a reverse transcriptase (RT) to induce small base edits in the DNA.

Figure 2. CRISPR-Cas gene editing in muscle-invasive bladder cancer research.

Short summary

This perspective details the current research using CRISPR-Cas gene editing technologies in the discovery of novel targets in muscle invasive bladder cancer. Furthermore, the future prospectives of these technologies have been discussed along with the current limitations and ethical considerations.